This site is intended for US healthcare professionals only.

For US healthcare professionals only.

ARNUITY is an inhaled corticosteroid indicated for the once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 5 years and older. ARNUITY is NOT indicated for the relief of acute bronchospasm.

Arnuity Containers

24-hour efficacy from an ICS.
One inhalation daily.
One easy-to-use ELLIPTA inhaler.1

Request Samples Restrictions apply.

"Easy to use" studied only in adults.

Samples & Savings

Help your patients get ARNUITY

Request samples and patient savings offers from the GSK Sample and Savings Offers Request Portal.

Pharmacology

Fluticasone Furoate: The Molecule

Learn what makes 24-hour ARNUITY different from fluticasone propionate.
ARNUITY container 100mg

ARNUITY 100 is an ICS proven to deliver continuous lung function improvement for a full 24 hours with ONE inhalation daily.2*

FEV1=forced expiratory volume in 1 second; ICS=inhaled corticosteroid; wm=weighted mean.

Learn more about ARNUITY.

Important Safety Information

Contraindications

  • ARNUITY is contraindicated for primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.
  • ARNUITY is contraindicated in patients with known severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to fluticasone furoate or any of the ingredients.

Warnings and Precautions

  • Oropharyngeal candidiasis has occurred in patients treated with ARNUITY. Advise patients to rinse the mouth with water without swallowing after inhalation.
  • ARNUITY is NOT a rescue medicine and should NOT be used for the relief of acute bronchospasm or symptoms. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.
  • Patients who use corticosteroids are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients.
  • Particular care is needed for patients transferred from systemic corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to ARNUITY.
  • Hypercorticism and adrenal suppression may occur with higher than the recommended dose or at the regular dosage of inhaled corticosteroids in susceptible individuals. If such changes occur, appropriate therapy should be considered.
  • Caution should be exercised when considering the coadministration of ARNUITY with long-term ketoconazole and other known strong CYP3A4 inhibitors (eg, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased systemic corticosteroid adverse effects may occur.
  • If paradoxical bronchospasm occurs, discontinue ARNUITY and institute alternative therapy.
  • Hypersensitivity reactions such as urticaria, flushing, allergic dermatitis, and bronchospasm may occur after administration of ARNUITY. Discontinue ARNUITY if such reactions occur.
  • Decreases in bone mineral density have been observed with long-term administration of products containing inhaled corticosteroids. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care prior to initiating ARNUITY and periodically thereafter.
  • Inhaled corticosteroids, as well as poorly controlled asthma, may cause a reduction in growth velocity, and the long-term effect on final adult height is unknown. Patients should be maintained on the lowest dose of inhaled corticosteroid that effectively controls their asthma. Monitor growth of children and adolescents.
  • Glaucoma, increased intraocular pressure, and cataracts have been reported following the long-term administration of inhaled corticosteroids; therefore, monitoring is warranted.

Adverse Reactions

  • Most common adverse reactions (≥5% of subjects ≥12 years of age) reported in a 24-week trial with ARNUITY 100 mcg (and placebo) were: nasopharyngitis 8% (5%), bronchitis 7% (6%), upper respiratory tract infection 6% (5%), headache 6% (4%).
  • Most common adverse reactions (≥5% of subjects ≥12 years of age) reported in a separate 24-week trial with ARNUITY 200 mcg (and 100 mcg) were: nasopharyngitis 13% (12%), headache 13% (10%), bronchitis 7% (12%), influenza 7% (4%), upper respiratory tract infection 6% (2%).
  • In a 12-week trial, adverse reactions (≥3% and greater than placebo) seen in subjects aged 5 to 11 years were similar to those reported in adult and adolescent subjects. Adverse reactions occurring in ≥3% of subjects treated with ARNUITY 50 mcg and greater than placebo were pharyngitis, bronchitis, and viral infection.
  • In a 24- to 76-week study, subjects with a history of 1 or more asthma exacerbations within the previous 12 months received fluticasone furoate 100 mcg. In addition to the events reported in the preceding 24-week trials, adverse events occurring in ≥3% of subjects treated with fluticasone furoate 100 mcg for up to 76 weeks included allergic rhinitis, nasal congestion, and arthralgia.

Use In Specific Populations

  • Use ARNUITY with caution in patients with moderate or severe hepatic impairment, as fluticasone furoate systemic exposure may increase by up to 3-fold. Monitor for corticosteroid-related side effects.
TOP

Please see full Prescribing Information, including Patient Information, for ARNUITY.

TOP

References

View all references

1004881R0 May 2018

References

  1. Data on file, GSK.
  2. Bleecker ER, Lötvall J, O'Byrne PM, et al. Fluticasone furoate–vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014;2(5):553-561.
  3. O’Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43(3):773-782.
  4. Lötvall J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med. 2014;108(1):41-49.
  5. Managed Markets Insight & Technology, LLC, Database as of November 2018.
  6. Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L660-L667.
  7. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007. http://www.nhlbi.nih.gov/­files/docs/guidelines/asthgdln.pdf. Updated August 28, 2007. Accessed May 23, 2018.
  8. Oliver AJ, Covar RA, Goldfrad CH, et al. Randomized trial of once-daily fluticasone furoate in children with inadequately controlled asthma. J Pediatr. 2016;178:246-253.e2.
1005066R0 May 2018